{"filing":{"accession_number":"0001104659-26-116685","cik":"0001889109","ticker":"BLTE","company_name":"BELITE BIO, INC","form":"6-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"tm2627719d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1889109/000110465926116685/tm2627719d1_6k.htm"},"events":[{"id":35908,"run_id":33096,"accession_number":"0001104659-26-116685","anchor_item_number":"EX-99.1","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"summary":"The exhibit announces Belite Bio's uplisting from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective October 19, 2026. While framed positively as a \"milestone,\" this is a material transfer of listing venue that reflects the company's achievement of compliance with the higher tier's \"more stringent financial and liquidity standards.\" The reverse of this event—failure to maintain listing standards—would constitute delisting risk; the uplisting itself is the favorable resolution of that risk and is material to investors assessing the company's market standing and capital access.","company_name":"BELITE BIO, INC","ticker":"BLTE","filing_date":"2026-10-19","form":"6-K","submitted_at":null,"items":[{"id":40137,"accession_number":"0001104659-26-116685","item_number":"EX-99.1","item_title":"tm2627719d1_ex99-1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The exhibit announces Belite Bio's uplisting from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective October 19, 2026. While framed positively as a \"milestone,\" this is a material transfer of listing venue that reflects the company's achievement of compliance with the higher tier's \"more stringent financial and liquidity standards.\" The reverse of this event—failure to maintain listing standards—would constitute delisting risk; the uplisting itself is the favorable resolution of that risk and is material to investors assessing the company's market standing and capital access.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-19T10:03:53.237942+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40137,"accession_number":"0001104659-26-116685","item_number":"EX-99.1","item_title":"tm2627719d1_ex99-1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The exhibit announces Belite Bio's uplisting from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective October 19, 2026. While framed positively as a \"milestone,\" this is a material transfer of listing venue that reflects the company's achievement of compliance with the higher tier's \"more stringent financial and liquidity standards.\" The reverse of this event—failure to maintain listing standards—would constitute delisting risk; the uplisting itself is the favorable resolution of that risk and is material to investors assessing the company's market standing and capital access.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-19T10:03:53.237942+00:00","company_name":"BELITE BIO, INC","ticker":"BLTE","filing_date":"2026-10-19"}]}